Several studies revealed the promising approach in anti-tumor therapy by combining conventional chemotherapy with the p38α and p38β inhibitor ralimetinib, demonstrating antiangiogenic and pro-apoptotic effects in tumor patients and in cell lines [22,24]. Here, MAPK11 is linked to neoplasm.